Breaking News, Financial News

Financial Report: Wyeth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Wyeth 2Q Revenues: $5.6 billion (+10%) 2Q Earnings: $1.2 billion (+13%) YTD Revenues: $11 billion (+10%) YTD Earnings: $2.5 billion (+12%) Comments: Pharmaceutical sales were $4.7 billion in the quarter, up 11%, driven by higher sales of Prevnar (+22%), Protonix (+25%), Enbrel (+37%), Nutrition products (+19%), and Zosyn (+17%). This increase was offset by lower sales of Zoton and Inderal LA due to generic competition. In the quarter, Lybrel and Torisel received FDA approval...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters